The COVID-19 Clinical Research Center, or CCRC, is a standalone research facility for the conduct of phase 1-3 clinical trials to find effective therapeutics and interventions for SARS-CoV-2, the virus that causes COVID-19. The CCRC offers the opportunity for collaboration by virologists, immunologists, epidemiologist, translational and physician scientists to apply their expertise to determine safe and effective therapies in partnership with health care providers, research institutes, and the biotech/pharmaceutical industry.
It will take a collaborative effort of researchers, scientists, health care providers and study participants to work together in stopping the COVID-19 pandemic. As a treatment and prevention resource, the CCRC will incorporate a diverse population of study participants to help in the local and international effort to deliver cures faster and prevent future outbreaks.
The COVID-19 Clinical Research Center conducts clinical studies of new COVID-19 interventions and therapeutics that can be safely administered and evaluated outside of a traditional hospital setting, increasing accessibility. The CCRC's research includes participants who have a desire to contribute to groundbreaking clinical research across a wide breadth of COVID-19-related studies.
The CCRC facility is a stand-alone building on the Fred Hutch campus. It is designed to support active COVID-19 research participants outside a hospital setting that prioritizes participant and staff safety.
We have addressed questions about the clinical studies and the safe conduct practices at the CCRC, as well as the most commonly asked questions about volunteer study participation.
The COVID-19 Clinical Research Center aims to collaborate with research partners who are developing and testing novel interventions to effectively treat the infection early and address post-acute symptoms, as well as prophylaxis methods to aid in infection prevention for those who may not be able to mount an adequate response to vaccines. Our research teams partner with area health care colleagues who share our drive to innovate, collaborate, and save lives to both identify participants and conduct clinical trials.
Dr. Rachel Bender lgnacio serves as the Medical Director of the CCRC. In addition to overseeing a team of on-site clinical and support staff, she'll also be responsible for ensuring that the trials are conducted safely and with best clinical and scientific practices. She has overseen the scientific and operational processes for clinical trials related to COVID-19 since the start of the pandemic. Dr. Bender Ignacio is an assistant professor in the Division of Allergy & Infectious Diseases in the University of Washington Department of Medicine and an associate in the Hutch's Vaccine and Infectious Disease Division.
Fatima Ranjbaran serves as the Operations Director of the CCRC. She oversees the overall operations of the facility and the onsite clinical and support staff. Ranjbaran has thirteen years of experience in infectious disease and cardiovascular research with her most recent role at UW Cardiology. With a background in nursing and biochemistry, she brings a mix of care for participants and confidence in the scientific method to her role.
In her role as Senior Vice President and Director of the Vaccine and Infectious Disease Division, Dr. Julie McElrath oversees COVID-19 research at Fred Hutch, including the launch of the COVID-19 Clinical Research Center. Her COVID-19 research program is focused on protective immunity to SARS-CoV-2, including leading the Seattle COVID-19 Cohort and vaccine development.
An international expert in virology and vaccine development, Dr. Larry Corey is a leader in the COVID-19 Prevention Network, which is part of a global strategic response to the COVID-19 pandemic.
Every dollar helps our scientists reduce the threat of the novel coronavirus.
820 Minor Ave N.
Seattle, WA 98109
1205 Aloha St.
Seattle, WA 98109